medRxiv preprint doi: https://doi.org/10.1101/2019.12.07.19011429; this version posted December 14, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

Informing Pharmacokinetic Models with Physiological Data:
Oral Population Modeling of L-Serine in Humans
J. R. Bosley1,*, Elias BjÃ¶rnson2,3, Cheng Zhang4, Hasan Turkez5, Jens Nielsen3, Mathias Uhlen4,
Jan Boren2, Adil Mardinoglu4,6,*

1

Clermont Bosley LLC, Philadelphia, PA, USA

2

Department of Molecular and Clinical Medicine, University of Gothenburg and Sahlgrenska University
Hospital, SE-413 45, Gothenburg, Sweden

3

Department of Biology and Biological Engineering, Chalmers University of Technology, SE-412 96,
Gothenburg, Sweden
4

Science for Life Laboratory, KTH - Royal Institute of Technology, SE-171 21, Stockholm, Sweden

5

Department of Molecular Biology and Genetics, Erzurum Technical University, Erzurum 25240, Turkey.

6

Centre for Hostâ€“Microbiome Interactions, Faculty of Dentistry, Oral & Craniofacial Sciences, King's
College London, London, SE1 9RT, United Kingdom

* Corresponding authors: JRB (jbosley@clerbos.com) and AM (adilm@scilifelab.se)

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2019.12.07.19011429; this version posted December 14, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

Abstract
To determine how to set optimal oral L-serine (serine) dose levels for a clinical trial, existing
literature was surveyed. Data sufficient to set the dose was inadequate, and so a (n=10) Phase IA calibration trial was performed, administering serine with and without other oral agents. We
analyzed the trial and the literature data using pharmacokinetic (PK) modeling and statistical
analysis. The therapeutic goal is to modulate specific serine-related metabolic pathways in the
liver using the lowest possible dose which gives the desired effect since the upper bound was
expected to be limited by toxicity. In this paper, we first review relevant literature, describe the
calibration trial and resulting data, and present the results of modeling from the trial. Serine is a
non-essential amino acid that is nonetheless present at a base level in blood from both dietary
sources and endogenous production. Serine is consumed by several pathways. A standard PK
approach, in which a common model structure was selected using a fit to data, yielded a model
with a single central compartment corresponding to plasma, clearance from that compartment,
and an endogenous source of serine. The lack of intravenous data normally prevents independent
determination of bioavailability and volume of distribution, however, under some assumptions
about endogenous synthesis and use, values could be estimated. The model was poorly
conditioned but did give consistent estimates. To improve conditioning, a parametric structure
was changed to estimate ratios (bioavailability over volume, for example). Model fit quality was
improved and the uncertainty in estimated parameters was reduced. Because of the particular
interest in the fate of serine, the model was used to estimate whether serine is consumed in the
gut, absorbed by the liver, or entered the blood in either a free state, or in a protein- or tissuebound state that is not measured by our assay. The PK model structure was set up to represent
relevant physiology, and this quantitative systems biology approach allowed a broader set of
physiological data to be used to narrow parameter and prediction confidence intervals, and to
better understand the biological meaning of the data. The model results allowed us to determine
the optimal human dose for future trials, including a trial design component including IV and
tracer studies. A key contribution is that we were able to use human physiological data from the
literature to inform the PK model and to set reasonable bounds on parameters, and to improve
model conditioning. Leveraging literature data produced a more predictive, useful model.

medRxiv preprint doi: https://doi.org/10.1101/2019.12.07.19011429; this version posted December 14, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

Introduction
L-Serine (serine), a non-essential amino acid (AA), is de novo synthesized from glucose via 3phosphoglycerate/3-phosphoserine and via interconversion of glycine. It can be obtained from
diet, the degradation of dietary proteins and phospholipids and consumed in the production of
pyruvate, amino acids (glycine, L-cysteine), and sphingosine and phosphatidyl serine. It also
may be racemized to D-serine. Serine has attracted interest in the treatment of neurodegenerative
diseases (de Koning et al., 2003), including Amyotrophic Lateral Sclerosis (Levine et al., 2017)
and neuropathy (Gantner et al., 2019; Garofalo et al., 2011; Scherer, 2011).
As shown in Figure 1 (after (de Koning et al., 2003)), serine can be part of key metabolic
pathways associated with proteins and carbohydrates, and supplemental serine is expected to
affect hepatic metabolism. Mardinoglu et al have used Genome Scale Metabolic (GEM)
modeling to infer that supplementation of serine may affect hepatic pathways that are relevant to
the pathology of non-alcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH)
(Mardinoglu et al., 2014). Experimentally, a positive effect of serine therapy had been reported
for alcoholic fatty liver in mice and rats (Sim et al., 2015). This led to a clinical trial of oral
serine, showing a significant reduction in hepatic fat (assessed via imaging) with concurrent
reduction of liver tissue markers (Mardinoglu et al., 2017). The trial data and further metabolic
modelling analysis was used to generate a more comprehensive therapy approach,
supplementation of metabolic cofactor formulation, of which serine is one of the component
(Mardinoglu et al., 2017, 2019).
Here, we aim to identify the optimal human dose of serine in this formulation to obtain the best
therapeutic effect, and to avoid adverse effects in future clinical trials. Understanding clinical
data and modeling the PK is complicated by the endogenous production of serine, predominantly
(perhaps solely) from the kidney (Kalhan and Hanson, 2012; Pitts and MacLeod, 1972) leading
to a measurable and significant baseline level in the blood.
Review and Analysis of Literature Data
The human kidney extracts AAs (significantly, glutamine and glycine) and secretes other amino
acids (in largest amounts, serine and alanine) (Pitts and MacLeod, 1972). Serine is extracted by
the liver and other tissues including skeletal muscle (Felig, 1975). Exercise does not appear to
affect serine concentration by more than five percent from the mean (Felig and Wahren, 1971).
Glycine is the major precursor of serine, but glycine uptake is not adequate to account for all
serine, and so glycolytic intermediates are also used by the body (Brosnan, 2003).
Published PK analysis of serine is sparse. (Pitts and MacLeod, 1972) reported values for volume
of distribution of 199L and 360L for dogs weighing 20 and 28kg (10L/kg and 12.9L/kg,
respectively). Baseline levels of serine in healthy subjects are published. A mean level (for five
subjects) of 1.12 (with SEM of 0.046) mg/100ml, equivalent to 106 (4.3) umol/L was reported
(Stein and Moore, 1954). These authors also cite a baseline serine level of 1.2 mg/100ml,
equivalent to 114 umol/L, as being reported (Kurt Schreier and Hans PlÃ¼ckthun, 1950). A
baseline serine value of 0.97 (0.07) mg/100ml, or 92.3 (6.3) umol/L was reported (Frame, 1958).
Neis et al, (Neis et al., 2017) reported a value, measured in the radial artery, of 97.2 (4.7) umol/L

medRxiv preprint doi: https://doi.org/10.1101/2019.12.07.19011429; this version posted December 14, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

and a value from the renal vein of 130 (8.4) umol/L, a positive difference (that is, kidneys
releasing serine) of 32.8 umol/L. Using a standard value for kidney blood perfusion of 1.2 L/m
(Calzia et al., 2005), and assuming that the assays capture all serine in the blood, we can estimate
the net endogenous renal release of serine as approximately 4.2 mg/min or 252 mg/hr. A much
higher estimate, which incorporates more detail, estimates serine production to be 150
umol//kg/h (Kalhan and Hanson, 2012), or about 1100 mg/hr. Endogenous production, at some
level, clearly must be represented in the model. Detailed analysis of other amino acids show a
time variation in concentration after meals in pigs (Stoll et al., 1998), and a similar variation in
human serine production might be expected.
Wilcox et al, (Wilcox et al., 1985) show a mean level of serine of approximately 131 (SD of 18.5
SD) ug/ml for nonpsychotic control subjects. Interestingly, the baseline level shown for
psychotics was 202.6 (SD 38) ug/ml, a difference that was reported as strongly significant
(p<0.0001). These researchers determined an approximately 50% lower serine hydroxy methyl
transferase (SHMT) enzyme activity in psychotic patients than in controls. The SHMT enzyme
cleaves serine in the pathway synthesizing glycine from serine.
Wilcox et al, (Wilcox et al., 1985) also administered an oral bolus of 4mM/kg of serine to 12
actively psychotic patients, and 10 nonpsychotic subjects. This is equivalent to about a 29.5 g
dose, for a 70kg subject. Using the oral dosing data, they found a range for serine elimination
half-life of between 1.85 and 14.81 hours presumably due, at least in part, to SHMT level
differences. There was a bimodal difference between active or previously active psychotic
patients, and non-psychotic patients with no such history. The variability for psychotic patients
was also much larger than for nonpsychotic subjects. The mean for non-psychotics was
approximately 3.2 hours, with a standard error of 0.09 hours. The differences reported in SHMT
may cause the longer half-life values and the higher baseline values. Clearly these factors must
be considered in safe serine dosing in psychotic patients.
Serine is extracted from the blood by the liver in two major ways. There is a first pass clearance
effect in which the liver extracts orally-dosed serine from the splanchnic circulation via the
portal vein. In piglets fed with a mix of amino acids (Stoll et al., 1998) found that this first-pass
metabolism in a fed state amounted to 58% of ingested serine. They also found that
quantitatively more of the absorbed essential amino acids were catabolized than were
incorporated into peptides and proteins. Hepatic extraction values for serine from arterial
circulation of 24.1 and 55.0% were observed in rats receiving a 13% or 50% casein diet
(Remesy et al., 1983). In roosters, a hepatic extraction value of 14% for serine was observed
(Song et al., 2001)
In humans after 10-12 hours fasting, It has been reported that the small extraction of serine, that
is the difference of 2.4 (5.1) umol/liter difference between portal vein and arterial concentration,
was statistically insignificant (Felig and Wahren, 1971). In their study, the reported arterial
serine concentration was 110.0 (11) umol/liter.
The mode of liver serine uptake is extraction of serine from the hepatic artery. Presumably this
occurs in both fed and fasting states. In humans, it has been showed (graphically) a drop between

medRxiv preprint doi: https://doi.org/10.1101/2019.12.07.19011429; this version posted December 14, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

arterial and hepatic vein concentrations of about 20 umol/liter, from a base of approximately 111
umol/liter in resting, postabsorptive (12-14 hour fast) state (Felig and Wahren, 1971). Again,
using a standard value for hepatic perfusion of 1.4 liters/minute (Calzia et al., 2005), this would
amount to 28umol/minute, or 3 mg/minute, or 180 mg/hr.
There is also extraction by muscle tissue. It has been reported that the arterio-femoral vein
difference of serine for subjects in a postabsorptive state (10-14 hours fasting) to be 10.5
umol/liter with a standard error of about 4 umol/liter, with the base arterial level to be 110.0 +/11 umol/liter (Felig and Wahren, 1971). This work also gave an estimate of total blood flow to
the legs, which was 0.9 (SEM 0.05) L/min. However, if a standard value for specific blood flow
to muscle of 0.08 L/kg/min and the body is assumed to be 42% muscle, a 70 kg human will have
muscle perfusion totaling 2.4 liters/minute (Calzia et al., 2005). If the serine extracted from all
muscle averages the same 10.5 umol/liter, this gives an approximation of 25 umol/minute, or 2.6
mg/minute, or 156mg/hour.
The fasting values of 4mg/minute released by the kidney, and 3 and 2.6 mg/minute uptake into
the liver and muscle, respectively, are approximations but the values can be used to check our
model for gross error.
Garlick (Garlick, 2001) assessed hazards of increased oral amino acid intake and noted that data
were sparse. Besides the paper by (Wilcox et al., 1985), which evaluated large doses (nearly 30g
equivalent in a 70kg subject) in 10 control and 12 psychotic subjects and noted no adverse
effects, a study of 4 actively psychotic schizophrenics by (Pepplinkhuizen et al., 1980) found that
administering 2mmol/kg (which would be about 13 g total, for a 60kg subject) of serine to four
female patients led to depersonalization in all, dysperception in 3, and euphoria and hallucination
in one. Additional effects were noted. In all, the effects occurred about 5 hours after
administration, and lasted 3-6 hours. None of the controls reacted to serine. This has
implications when administering serine to trial subjects or patients with high baseline serine
levels. It should be noted that serine does racemize to its enantiomer D-serine, and that D-serine
is being investigated in schizophrenia â€“ as a potential therapy (Kantrowitz et al., 2010, 2015), or
as a therapy in combination with other therapies (Tsai et al., 1998) (Heresco-Levy et al., 2005).
(Levine et al., 2017) administered doses of 0.5, 2.5, 7.5, and 15g of serine twice a day in a trial
with ALS (Amytrophic Lateral Schlerosis). While three of the 19 subjects died during the trial,
in line with expected mortality for the cohort of ALS patients tested. Adverse effects which may
be due to serine included one withdrawal due to bloating in one 15g b.i.d. patient.

medRxiv preprint doi: https://doi.org/10.1101/2019.12.07.19011429; this version posted December 14, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

Results â€“ Clinical Trial
Ten participants were recruited. All subjects were made aware of the risks inherent in the trial,
and all agreed to participate. The study was performed in accordance with the Declaration of
Helsinki and it was approved by the Ethics Committee at the Koc University, Istanbul, Turkey.
Each subject gave written informed consent before participation in the study. The clinical trial
was registered at ClinicalTrials.gov (with identifier: NCT03838822). Time limitations in
recruiting limited trial subjects to males (future trials will include both sexes). One subject
(subject 9) is a Type 1 diabetic and the other subjects were generally healthy. One subject
(subject 10) had received the cocktail during the preceding two weeks, but that subjectâ€™s results
were unremarkable and very close to responses of other subjects. Demographic data are
summarized in Table 1. The protocol covered five days. All dosing was oral, in the morning
after an overnight fast. On the first day, all subjects received 1 g of nicotinamide riboside. On
day two, all subjects received 3 g of L-carnitine. On day three, all subjects received 5 g of Nacetyl cysteine. On day four, all subjects received a â€œcocktailâ€ comprising the same dosing of
NR, L-Carnitine, and NAC, and 20 g of serine. On day 5, a 20 g dose of serine alone was
administered. Blood samples were taken every day (with number of samples per day being 2, 2,
1, 8, and 1 for days 1-5, respectively) and were analyzed for serine. Additional results are
reported elsewhere. Here, we report only serine.
Serine was supplied as a powder. 20 g doses were prepared by weight and administered after
mixing with 200 gr of water. There were no adverse effects reported by the participants during
the trial. A trellis plot of the data for serine concentration over time is shown Figure 2. It is clear
that a non-zero baseline value for serine is observed in all subjects. The average of the (pre-dose
or baseline) serine values was 117 (6.7) umol/L, consistent with reported values given in the
literature cited.
Modeling and Analysis
Figure 2A and 2B show the data on one plot, time-shifted so that the first dose was at time zero.
The model trace shown in the figures is from a linear model, with mass action absorption of
serine from a gut compartment to a plasma compartment subject to a bioavailability, mass action
clearance from the plasma, and a constant endogenous biosynthesis being added to the plasma
compartment. This is represented graphically in Figure 3. The modeling equations used were as
follows. First, the amount of serine in the gut dose compartment, D, is
ð‘‘ð‘‘ð‘‘ð‘‘
ð‘‘ð‘‘ð‘‘ð‘‘

= âˆ’ð‘˜ð‘˜ð‘Žð‘Žð‘Žð‘Žð‘Žð‘Ž ð·ð· + ð·ð·ð·ð·ð·ð·ð·ð·ð·ð·ð·ð·ð·ð· âˆ— ð›¿ð›¿(ð‘¡ð‘¡ âˆ’ ð‘¡ð‘¡ð·ð·ð·ð·ð·ð·ð·ð· ) ð¶ð¶

Eq. 1

Where d is the Dirac delta function and DoseAmt is the bolus dose quantity.
The equation for Serine concentration, C, with five adjustable parameters, (VD, F, kabs, kgen and
CL) is
ð‘‰ð‘‰ð·ð·

ð‘‘ð‘‘ð‘‘ð‘‘
ð‘‘ð‘‘ð‘‘ð‘‘

= ð¹ð¹ ð‘˜ð‘˜ð‘Žð‘Žð‘Žð‘Žð‘Žð‘Ž ð·ð· + ð‘˜ð‘˜ð‘”ð‘”ð‘”ð‘”ð‘”ð‘” âˆ’ ð¶ð¶ð¶ð¶ ð¶ð¶

Eq. 2

medRxiv preprint doi: https://doi.org/10.1101/2019.12.07.19011429; this version posted December 14, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

Where C denotes serine concentration, VD is the apparent volume of distribution of serine, F is
bioavailability, kabs is a rate constant for absorption, kgen denotes a constant endogenous serine
production rate, CL is serine clearance.
One modeling assumption that should be highlighted is that endogenous serine production is
assumed constant. One conclusion is that the administered dose of serine is virtually cleared
within 12 hours.
Note that without a pre-existing value for the volume of distribution or bioavailability, this form
of equation is usually poorly conditioned and any set of parameters (VD, F, kabs, kgen and CL) that
fits data could be scaled by an arbitrary amount to fit the data equally well. Nonetheless, a leastsquares fitting process using naÃ¯ve pooled technique did converge to a volume of about 1 liter.
We know that this is likely not correct, as (Pitts and MacLeod, 1972) estimated volumes for dogs
of approximately 160 liter. Parameter values are shown in Table 2. The individual data, and the
naive pooled model results are plotted in figures 2A and 2B.
The terminal clearance coefficient (CL/VD, i.e. the rate of endogenous generation) is 0.48/hr.
This is equivalent to a half-life of 1.45 hours, a bit lower than reported by (Wilcox et al., 1985).
The rate of endogenous generation is calculated (CL * baseline) as 6.6 mg/hour, significantly
lower than discussed above. This assumes a volume of distribution of about 1 liter, though,
which is significantly at odds with the 199 and 260 liter values for dogs cited by (Pitts and
MacLeod, 1972).
In addition to the non-physiological value for volume, the previous fit uses a naÃ¯ve pooled-date
approach and hence does not represent any subject very well, as the averaging process distorts
absorption and clearance parameters and yields unrepresentative values for, for example,
predicted maximum concentration, or Cmax. This motivated the use of population modeling.
The model may be modified to improve conditioning and to allow more detailed representation
of the physiology discussed above so as to allow the use of a wider range of data. Also, one
desired use for the model was to simulate clinical trials. Models that represent an average
patients, but not any individual patient are not adequate for these tasks.
Model fitting without prior knowledge of volume (or bioavailability) will require modification to
equation 2 to improve conditioning as shown:
ð‘‘ð‘‘ð‘‘ð‘‘
ð‘‘ð‘‘ð‘‘ð‘‘

=

ð¹ð¹

ð‘‰ð‘‰ð·ð·

ð‘˜ð‘˜ð‘Žð‘Žð‘Žð‘Žð‘Žð‘Ž ð·ð· +

ð‘˜ð‘˜ð‘”ð‘”ð‘”ð‘”ð‘”ð‘”
ð‘‰ð‘‰ð·ð·

âˆ’

ð¶ð¶ð¶ð¶

ð‘‰ð‘‰ð·ð·

ð¶ð¶

Eq. 3

This reduces the degrees of freedom by one, as the fitting must solve only for four adjustable
constant parameters, (F/VD, kabs, kgen/VD and CL/VD).
To generate parameter estimates and distributions, and to understand parametric distribution and
confidence intervals for model prediction, we proceeded to use population pharmacometric
approaches to modeling (Mould and Upton, 2013; Owen and Fiedler-Kelly, 2014; Upton and
Mould, 2014, 2014).

medRxiv preprint doi: https://doi.org/10.1101/2019.12.07.19011429; this version posted December 14, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

The model was first implemented in SimBiology (MathWorks Inc., Natick MA, USA).
SimBiology allows a graphical approach to model building. The picture of the model has
underlying mathematics, and fitting and data manipulation can be done using integrated
software. The model is pictured in Figure 3.
Before applying population methods, a first step in fitting this model was to fit each subject
individually. This was done using the nonlinear least-squares (lsqnonlin) routine. The mixed
(constant plus proportional) error model was found to give the best results. The results are
shown in Figure 4 and parameter estimates are given in Table 3.
Again, the mean values given cannot be guaranteed to actually represent any individual. That is,
using these parameters in a simulation may result in an outcome that is not physiologically
feasible or reasonable. A way to achieve mean parameters that are representative is to use a
population approach. The nlmefit (non-linear mixed effect modeling) routine in SimBiology
(MathWorks Inc, Natick, MA) was used using a combined (constant plus proportional) error
model. The approach yielded the fits shown below:
The resulting parameters are given in Table 4. What is striking is just how small the variabilities
for several parameters are. Most of the variability is in the bioavailability (F/V) parameter. The
parameters were estimated as following a lognormal distribution, and so the parameter values
estimated as the natural logarithm of the parameter, with standard errors are in logarithmic terms.
To give ranges in meaningful units, the exponential of the nominal value and the nominal value
plus and minus one standard error were calculated. Model results are plotted in Figure 5.
To check these results, the same model was programed in NONMEMÂ® (ICON Plc, Ellicott City,
MD). Parameter distribution was implemented as lognormal. The proportional error model gave
nearly the same results as the mixed model, and so proportional error was used. The results for
the proportional error model are given in Table 5.
The Eta values that are shown as small were so small as to not allow noticeable variability (no
change in 3 significant figures) and could be fixed in the estimation scheme. We note that the
variability in the NONMEM parameters yields qualitatively different result than observed with
nlmefit. One plausible explanation is that the two approaches found different local minima
(Ricardo Paxson and Florian Augustin of MathWorks Inc, personal communication) as
parameter variance estimates in nlmefit initially are set to zero, while in NONMEMÂ®, these
values may be initialized via the OMEGA vector or matrix.
We evaluated whether a second compartment improved the model. The improvement in the loglikelihood-based NONMEM metric (967.5 vs 979.785 for the one compartment model) lead to a
difference of 12.2 which is more than the threshold of 5.99 (Dennis Fisher and Steven Shafer,
2007) and would justify the addition of two additional parameters (rate-law constants k23 and
k32). However, the fitted value of these parameters were four orders of magnitude less than
clearance and absorption rate constants and resulted in other parameter estimates changing only
in the third decimal place with a change in predicted values that was trivial in relation to serine
concentration. The additional compartment complexity was rejected on this basis.

medRxiv preprint doi: https://doi.org/10.1101/2019.12.07.19011429; this version posted December 14, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

We evaluated weight and height as potential covariates. Of the two parameters that showed
variation between subjects, neither was shown to be correlated in any way to either metric.
Likewise, there were no meaningful trends observed between other metrics (e.g. residual values)
and weight and height. Our final model did not include covariates.
Discussion
By using a model that was consistent with physiology, a broad range of published data for serine
was able to be exploited. Model structure was improved, and we were able to build confidence
in some fitted parameters (such as endogenous production rate). Animal extraction data (Neis et
al., 2017) were used to estimate bioavailability (~60%) and ultimate hepatic serine uptake
fraction (75%). We were able to reject reported volume of distribution values from animal data
(Pitts and MacLeod, 1972) as inappropriate for scaling to humans. Without intravenous data, a
value for volume of distribution was estimated for serine (~140L).
The dosing of 20 g QD in normal patients did not elicit any adverse effects in our clinical trial.
The work of Wilcox et al. (Wilcox et al., 1985) noted no adverse effects in normal and psychotic
subjects for a dose of 4 mM/kg, which is equivalent to 0.424 g/kg, or a 29.7 g dose for a 70 kg
subject. Wilcox et al. (Wilcox et al., 1985) did note a higher baseline serine value, and lower
SHMT activity, in psychotic subjects, and (Pepplinkhuizen et al., 1980) did observe
schizophrenia-like psychoses induced in four active female schizophrenics (2 mM/kg, or 0.212
g/kg, equivalent to 12.7 g dose in a 60kg women). This suggests, but does not prove, that a dose
of 20g or less may be tolerated in those who are not actively psychotic. Given that biopsy and/or
tracer studies for SHMT activity are intrusive, a baseline serine value should be considered as an
inclusion/exclusion test for future trials.
With that said, the 75% overall hepatic extraction with a 20 g dose lead to 15 g absorbed by the
liver. Averaging this over 24 hours yields 10.4 mg/minute â€“ a bit more than twice the current
value of endogenous production, from clinical measurements. Thus, a 20g daily dose is expected
to approximately triple hepatic serine uptake. Alternately, an approximately 12 g dose twice a
day could be considered, due to the quick clearance of serine.
Systems modeling allowed the use of a broader set of data to expand our understanding of trial
results. Reported parameters were used to rule out our first naÃ¯ve pooled model, and to bound
parameters in our population PK model. The population PK model was then used to inform our
dosing decision for an upcoming trial. The modeling also highlighted the need to determine
volume of distribution and bioavailability.
What was not considered was the variation of serine release and uptake during the day. We
believe that this variability is inconsequential for our purpose of dose-setting, but the model
could be augmented should this variation be relevant. We did not include the extraction of serine
by the brain, but this could be easily analyzed using a modification of the current model and
relevant trial data, for example using the results of (Levine et al., 2017), and a completed trial of
serine in neuropath (Fridman et al., 2019) .

medRxiv preprint doi: https://doi.org/10.1101/2019.12.07.19011429; this version posted December 14, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

A key interest in dose determination for serine is estimating the amount absorbed by the liver.
Hepatic extraction will be both first-pass, from splanchnic circulation into the hepatic portal
vein, and also system extraction from arterial circulation. Supposing that the 24.1 or 55 percent
extraction range observed by (Remesy et al., 1983) in rats applies to humans, and assuming other
use (for example, bacterial consumption in the gut) is negligible, this would imply a standard
oral bioavailability values of 75.9 and 45%. Using the fitted value for F/V of 0.00429 gives
values of volume of distribution of 177 and 104L. The question is whether these numbers and
ranges are physiological.
It has been reported that the values for volume of distribution of 199L and 360L for dogs
weighing 20 and 28kg (10L/kg and 12.9L/kg, respectively, must be scaled (Pitts and MacLeod,
1972). One source gives blood volume in dogs as 79 ml of blood per kg of body weight
(Courtice, 1943). From this, we can calculate blood volume estimates of 1.580 and 2.212 liters.
Allometric scaling principles suggest that these values might be scaled proportionally to body
weight (Holford and Anderson, 2007), yielding (for both dogs) a value of about 5.5 liters of
blood for a 70kg human, only about 10% higher than the commonly used value of 5 liters. The
volume of distributions from dogs can be scaled proportionally to weight, yielding 700 and 900
liters. Using the average value of 800 liters, and 0.00429 for F/V gives an infeasible
bioavailability of 340%. This suggests that the volume of distribution of serine reported for dogs
(Pitts and MacLeod, 1972) is not appropriate or useful for humans, or at least that allometric
scaling was not correct. Because of this, and because we suspect that extraction may be a more
intrinsically conserved between species, the hepatic extraction values reported in rats (Remesy
et al., 1983) were used to generate bioavailability. A bioavailability of about 0.6 (roughly the
average between the 0.759 and 0.45 values in rats) yielded an effective volume of distribution of
about 140 liters.
Of key interest is the fate of the approximately 60% of serine that is not initially absorbed by the
liver. Recall the estimate above that the liver consumed about 3mg/minute, and the muscle
tissue about 2.6 mg/minute. Assuming that these are the major consumers of arterial serine yields
an estimate of arterial serine clearance of 46% by muscle and 54% by the liver. These values
suggest that the liver extracts about 73% (40% initially, and another 46% of the 60% of serine
that ends up in plasma) of ingested serine, with the rest going to muscle. This number is
probably high, as some of the arterial serine is likely extracted by tissues other than muscle.
The population fit of endogenous serine generation was estimated to be 29.6umol/L/hr, as
kgen/V. When multiplied by the estimated volume of 140L, this gives 440.0 mg/hour. This
must be compared with the 252 mg/hour estimated from (Neis et al., 2017), and the 1110
mg/hour estimated from the work of (Kalhan and Hanson, 2012) which was felt to be high.
Given differences in protocols, subjects, and variability of measurements, these value does not
compare unfavorably, and provide some confidence in the model analysis.
If 440mg is generated endogenously every hour, and the liver accounts for the uptake of 54% of
that amount, normal liver uptake of serine is about 6 g of serine per day. An oral dose of 8 g/day
(6 g/73% liver utilization for oral dosing) could approximately double liver uptake, and a dose of
16 g/day could be expected to triple liver uptake, provided the extraction values considered here

medRxiv preprint doi: https://doi.org/10.1101/2019.12.07.19011429; this version posted December 14, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

did not change. Earlier experiments with once-per-day 20g dosing (Mardinoglu et al., 2017)
gave good results in some subjects, weaker responses in others. Noting that daily dosing up to
about 30 g have been administered to normal subjects without adverse effects, and desiring a
stronger effect suggested that a prudent upper bound would be a total of 25g per day. Given that
the serine is apparently cleared quickly and a sustained metabolic effect is desired, the
recommended 25 g dose could be administered as 12.5 g, twice a day. This was the
recommendation for the upcoming trial. A more comprehensive clinical trial is planned and will
be executed. A portion of that trial will include intravenous dosing to allow a better
determination of bioavailability. In addition, we expect to use tracer studies to confirm hepatic
extraction values derived from the model.
Acknowledgements
The authors are grateful to Mr. Ricardo Paxson and Dr. Florian Augustin of Mathworks, Inc. for
their helpful criticisms and insight into the Simbiology nlme fitting routine.
References
Brosnan, J.T. (2003). Interorgan amino acid transport and its regulation. J. Nutr. 133, 2068S2072S.
Calzia, E., IvÃ¡nyi, Z., and Radermacher, P. (2005). Determinants of blood flow and organ
perfusion. In Functional Hemodynamic Monitoring, (Springer), pp. 19â€“32.
Courtice, F.C. (1943). The blood volume of normal animals. J. Physiol. 102, 290â€“305.
Dennis Fisher, and Steven Shafer (2007). Fisher/Shafer NONMEM Workshop Pharmacokinetic
and Pharmacodynamic Analysis with NONMEM Basic Concepts.
Felig, P. (1975). Amino acid metabolism in man. Annu. Rev. Biochem. 44, 933â€“955.
Felig, P., and Wahren, J. (1971). Amino acid metabolism in exercising man. J. Clin. Invest. 50,
2703â€“2714.
Frame, E.G. (1958). The levels of individual free amino acids in the plasma of normal man at
various intervals after a high-protein meal. J. Clin. Invest. 37, 1710â€“1723.
Fridman, V., Suriyanarayanan, S., Novak, P., David, W., Macklin, E.A., McKenna-Yasek, D.,
Walsh, K., Aziz-Bose, R., Oaklander, A.L., and Brown, R. (2019). Randomized trial of l-serine
in patients with hereditary sensory and autonomic neuropathy type 1. Neurology 92, e359â€“e370.
Gantner, M.L., Eade, K., Wallace, M., Handzlik, M.K., Fallon, R., Trombley, J., Bonelli, R.,
Giles, S., Harkins-Perry, S., Heeren, T.F.C., et al. (2019). Serine and Lipid Metabolism in
Macular Disease and Peripheral Neuropathy. N. Engl. J. Med. 381, 1422â€“1433.
Garlick, P.J. (2001). Assessment of the safety of glutamine and other amino acids. J. Nutr. 131,
2556S-61S.

medRxiv preprint doi: https://doi.org/10.1101/2019.12.07.19011429; this version posted December 14, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

Garofalo, K., Penno, A., Schmidt, B.P., Lee, H.-J., Frosch, M.P., von Eckardstein, A., Brown,
R.H., Hornemann, T., and Eichler, F.S. (2011). Oral L-serine supplementation reduces
production of neurotoxic deoxysphingolipids in mice and humans with hereditary sensory
autonomic neuropathy type 1. J. Clin. Invest. 121, 4735â€“4745.
Heresco-Levy, U., Javitt, D.C., Ebstein, R., Vass, A., Lichtenberg, P., Bar, G., Catinari, S., and
Ermilov, M. (2005). D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine
for treatment-refractory schizophrenia. Biol. Psychiatry 57, 577â€“585.
Holford, N.H.G., and Anderson, B.J. (2007). Mechanism-Based Concepts of Size and Maturity
in Pharmacokinetics. Annu Rev Pharmacol Toxicol 48, 303â€“332.
Kalhan, S.C., and Hanson, R.W. (2012). Resurgence of serine: an often neglected but
indispensable amino Acid. J. Biol. Chem. 287, 19786â€“19791.
Kantrowitz, J.T., Malhotra, A.K., Cornblatt, B., Silipo, G., Balla, A., Suckow, R.F., Dâ€™Souza, C.,
Saksa, J., Woods, S.W., and Javitt, D.C. (2010). High dose D-serine in the treatment of
schizophrenia. Schizophr. Res. 121, 125â€“130.
Kantrowitz, J.T., Woods, S.W., Petkova, E., Cornblatt, B., Corcoran, C.M., Chen, H., Silipo, G.,
and Javitt, D.C. (2015). D-serine for the treatment of negative symptoms in individuals at clinical
high risk of schizophrenia: a pilot, double-blind, placebo-controlled, randomised parallel group
mechanistic proof-of-concept trial. Lancet Psychiatry 2, 403â€“412.
de Koning, T.J., Snell, K., Duran, M., Berger, R., Poll-The, B.-T., and Surtees, R. (2003). Lserine in disease and development. Biochem. J. 371, 653â€“661.
Kurt Schreier, and Hans PlÃ¼ckthun (1950). Untersuchungen Ã¼ber den Gehalt an freien
AminosÃ¤uren im Serum und Urin. Biochem. Z. 320, 447â€“465.
Levine, T.D., Miller, R.G., Bradley, W.G., Moore, D.H., Saperstein, D.S., Flynn, L.E., Katz,
J.S., Forshew, D.A., Metcalf, J.S., and Banack, S.A. (2017). Phase I clinical trial of safety of Lserine for ALS patients. Amyotroph. Lateral Scler. Front. Degener. 18, 107â€“111.
Mardinoglu, A., Agren, R., Kampf, C., Asplund, A., Uhlen, M., and Nielsen, J. (2014). Genomescale metabolic modelling of hepatocytes reveals serine deficiency in patients with non-alcoholic
fatty liver disease. Nat. Commun. 5, 3083.
Mardinoglu, A., Bjornson, E., Zhang, C., Klevstig, M., SÃ¶derlund, S., StÃ¥hlman, M., Adiels, M.,
Hakkarainen, A., Lundbom, N., Kilicarslan, M., et al. (2017). Personal modelâ€assisted
identification of NAD+ and glutathione metabolism as intervention target in NAFLD. Mol. Syst.
Biol. 13, 916.
Mardinoglu, A., Ural, D., Zeybel, M., Yuksel, H.H., UhlÃ©n, M., and BorÃ©n, J. (2019). The
Potential Use of Metabolic Cofactors in Treatment of NAFLD. Nutrients 11, 1578.

medRxiv preprint doi: https://doi.org/10.1101/2019.12.07.19011429; this version posted December 14, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

Mould, D.R., and Upton, R.N. (2013). Basic Concepts in Population Modeling, Simulation, and
Model-Based Drug Developmentâ€”Part 2: Introduction to Pharmacokinetic Modeling Methods.
CPT Pharmacomet. Syst. Pharmacol. 2, e38.
Neis, E.P.J.G., Sabrkhany, S., Hundscheid, I., Schellekens, D., Lenaerts, K., Damink, S.W.O.,
Blaak, E.E., Dejong, C.H.C., and Rensen, S.S. (2017). Human splanchnic amino-acid
metabolism. Amino Acids 49, 161â€“172.
Owen, J.S., and Fiedler-Kelly, J. (2014). Introduction to Population Pharmacokinetic /
Pharmacodynamic Analysis with Nonlinear Mixed Effects Models (John Wiley & Sons).
Pepplinkhuizen, L., Bruinvels, J., Blom, W., and Moleman, P. (1980). Schizophrenia-like
psychosis caused by a metabolic disorder. Lancet Lond. Engl. 1, 454â€“456.
Pitts, R., and MacLeod, M. (1972). Synthesis of serine by the dog kidney in vivo. Am. J.
Physiol.-Leg. Content 222, 394â€“398.
Remesy, C., Fafournoux, P., and Demigne, C. (1983). Control of hepatic utilization of serine,
glycine and threonine in fed and starved rats. J. Nutr. 113, 28â€“39.
Scherer, S.S. (2011). The debut of a rational treatment for an inherited neuropathy? J. Clin.
Invest. 121, 4624â€“4627.
Sim, W.-C., Yin, H.-Q., Choi, H.-S., Choi, Y.-J., Kwak, H.C., Kim, S.-K., and Lee, B.-H.
(2015). L-serine supplementation attenuates alcoholic fatty liver by enhancing homocysteine
metabolism in mice and rats. J. Nutr. 145, 260â€“267.
Song, Z., Beers, K., Dibner, J.J., VÃ¡zquez-AÃ±Ã³n, M., McNew, R., and Bottje, W. (2001). The
hepatic extraction of plasma free amino acids and response to hepatic portal venous infusion of
methionine sources in anesthetized SCWL males (Gallus domesticus). Comp. Biochem. Physiol.
B Biochem. Mol. Biol. 130, 237â€“250.
Stein, W.H., and Moore, S. (1954). The free amino acids of human blood plasma. J. Biol. Chem.
211, 915â€“926.
Stoll, B., Henry, J., Reeds, P.J., Yu, H., Jahoor, F., and Burrin, D.G. (1998). Catabolism
dominates the first-pass intestinal metabolism of dietary essential amino acids in milk protein-fed
piglets. J. Nutr. 128, 606â€“614.
Tsai, G., Yang, P., Chung, L.-C., Lange, N., and Coyle, J.T. (1998). D-serine added to
antipsychotics for the treatment of schizophrenia. Biol. Psychiatry 44, 1081â€“1089.
Upton, R.N., and Mould, D.R. (2014). Basic Concepts in Population Modeling, Simulation, and
Model-Based Drug Development: Part 3â€”Introduction to Pharmacodynamic Modeling
Methods. CPT Pharmacomet. Syst. Pharmacol. 3, e88.
Wilcox, J., Waziri, R., Sherman, A., and Mott, J. (1985). Metabolism of an ingested serine load
in psychotic and nonpsychotic subjects. Biol. Psychiatry 20, 41â€“49.

medRxiv preprint doi: https://doi.org/10.1101/2019.12.07.19011429; this version posted December 14, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

medRxiv preprint doi: https://doi.org/10.1101/2019.12.07.19011429; this version posted December 14, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

Figure Legends

Figure 1. Production (red line) and use (black lines) of L-serine in the body. Modified from (de
Koning et al., 2003)

medRxiv preprint doi: https://doi.org/10.1101/2019.12.07.19011429; this version posted December 14, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

A)

B)

Figure 2 Plots of data, time-shifted so that the initial dose time is 0 hours. This resulted in the
second dose time varying between 25.3 and 26.3 hours, shown as a horizontal bar in the figures.
A naÃ¯ve pooled model (dashed black line) is plotted with the individual data (colored dots and
solid lines). A) Linear plot. B) Semi-logarithmic plot

medRxiv preprint doi: https://doi.org/10.1101/2019.12.07.19011429; this version posted December 14, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

Figure 3 Graphical model representation from SimBiology(R)

medRxiv preprint doi: https://doi.org/10.1101/2019.12.07.19011429; this version posted December 14, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

Individual Fit
Group 3

Group 2

Group 1

OBS1 (Serine)

1000

PRED1 (Plasma.Serine)

800

600

400

Concentration

200

Group 4

Group 5

Group 6

Group 7

Group 8

Group 9

1000

800

600

400

200

Group 10

0

20

40

60

80

100

0

120

20

40

60

80

100

120

Time

Figure 4 Results for fitting each subject individually, using a nonlinear least-squares routine
with combined (constant plus proportional) error model. Clinical data (+) and model simulation
(line)

medRxiv preprint doi: https://doi.org/10.1101/2019.12.07.19011429; this version posted December 14, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

Population Fit
10

Group 1

5

Group 2

Group 3
OBS1 (Serine)

10

PRED1 (Serine_conc)

8

6

4

Concentration

2

10

5

Group 4

Group 5

Group 6

Group 7

Group 8

Group 9

10

8

6

4

2

Group 10

0

20

40

60

80

100

120

0

20

40

60

80

100

Time

Figure 5 Results for fitting all subjects using a population fit and a combined (constant plus
proportional) error model. Clinical data (+) and model simulation (line)

120

medRxiv preprint doi: https://doi.org/10.1101/2019.12.07.19011429; this version posted December 14, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

Random Effects Box Plot

0.2

0.15

0.1

Random Effects (b)

0.05

0

-0.05

-0.1

-0.15

-0.2

log(kabs)

log(FoV)

log(kcloV)

log(kgenoV)

ln(kabs) ln(F/V) ln(CL/V) ln(kgen/V)

Figure 6 A) (above) Box and whisker plot of estimated parameters from population fit. Most
variability is in the F/VD parameter. B) (at right) Plot of residuals to evaluate normality using a
combined (constant plus proportional) error model. The combined model gave improved
normality in the "tails" at both low and high values shown here, as opposed to a constant error
model.

medRxiv preprint doi: https://doi.org/10.1101/2019.12.07.19011429; this version posted December 14, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

Table 1 Trial subject demographic data
N=10
Mean
Std Dev.
Median
Minimum
Maximum

Weight(kg)
82.8
16.5
78.9
61.0
114.8

Height(cm)
177.0
8.3
175.0
166.0
192.5

BMI
26.4
4.5
25.3
19.4
34.5

Table 2 Naive pooled fitted parameters for the poorly conditioned model shown in Figures 2A
and 2B
Dose
20
g

ka
F
CL
baseline
V
Absorption bioavailability Clearance concentration Volume
0.829
0.00452
0.446
1.474
0.936
1/hour
dimensionless
L/hour
mg/100ml
liter

Table 3 Parameters from individual fit.
Mean
Std Dev
Minimum
Maximum
Units

kabs
4.67
3.33
0.51
15.6
1/hour

F/V x 1000
4.94
0.96
3.47
6.51
1/liter

CL/VD
0.346
0.087
0.198
0.505
1/hour

kgen/ VD
35.8
11.0
20.6
54.5
umol/(hr*liter)

Table 4 Parameters from population fit using SimBiologyÂ® nlmefit with proportional error model
Population
Pop - SEM
Pop + SEM
Minimum
Maximum
Units

kabs
2.88
1.88
4.42
2.88
2.89
1/hour

F/V x 1000
4.29
3.96
4.64
3.47
4.87
1/liter

CL/VD
0.288
0.266
0.312
0.288
0.288
1/hour

kgen/ VD
29.6
27.0
32.3
29.6
29.6
umol/(hr*liter)

CL/VD
0.312
0.0135
1/hour

kgen/ VD
32.1
Small (FIXed)
umol/(hr*liter)

Table 5 Population fit parameters from NONMEM.
Population
Eta value
Units

kabs
2.75
0.921
1/hour

F/V x 1000
4.58
Small (FIXed)
1/liter

